Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasper Dingemanse

Showing results (71-80 of 246) with videos related to

Pageof 25
Sort By:
European Journal of Clinical Pharmacology|January 22, 2013
Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatinMatthias Hoch, Petra Hoever, Rudolf Theodor, et al.
European Journal of Clinical Pharmacology|April 15, 2014
Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882Jasper Dingemanse, Laurent B Nicolas, Luc van Bortel
Journal of Cardiovascular Pharmacology|May 22, 2002
Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonistJasper Dingemanse, Martine Clozel, Paul L M van Giersbergen
European Journal of Clinical Pharmacology|July 24, 2002
Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonistPaul L M van Giersbergen, Frédéric Bodin, Jasper Dingemanse
Journal of Pharmaceutical Sciences|March 8, 2014
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazemJasper Dingemanse, Hans Gabriel Cruz, Martine Gehin, et al.
European Journal of Clinical Pharmacology|October 5, 2018
Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studiesMarie-Laure Boof, Abir Alatrach, Mike Ufer, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 5, 2023
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarctionMartine Gehin, Robert F Storey, Corine Bernaud, et al.
Clinical and Translational Science|August 30, 2020
Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P<sub>1</sub> R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White SubjectsPierre-Eric Juif, Jasper Dingemanse, Peter Winkle, et al.
Clinical Pharmacology in Drug Development|October 16, 2020
Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian SubjectsMagda S C Fontes, Jasper Dingemanse, Patricia N Sidharta
Journal of Clinical Pharmacology|September 19, 2015
Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female SubjectsNoémie Hurst, Matthias Pellek, Jasper Dingemanse, et al.
Pageof 25

Showing results (71-80 of 246) with videos related to

Sort By:
Pageof 25
European Journal of Clinical Pharmacology|January 22, 2013
Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatinMatthias Hoch, Petra Hoever, Rudolf Theodor, et al.
European Journal of Clinical Pharmacology|April 15, 2014
Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882Jasper Dingemanse, Laurent B Nicolas, Luc van Bortel
Journal of Cardiovascular Pharmacology|May 22, 2002
Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonistJasper Dingemanse, Martine Clozel, Paul L M van Giersbergen
European Journal of Clinical Pharmacology|July 24, 2002
Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonistPaul L M van Giersbergen, Frédéric Bodin, Jasper Dingemanse
Journal of Pharmaceutical Sciences|March 8, 2014
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazemJasper Dingemanse, Hans Gabriel Cruz, Martine Gehin, et al.
European Journal of Clinical Pharmacology|October 5, 2018
Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studiesMarie-Laure Boof, Abir Alatrach, Mike Ufer, et al.
Expert Opinion on Drug Metabolism & Toxicology|October 5, 2023
Clinical pharmacology of selatogrel for self-administration by patients with suspected acute myocardial infarctionMartine Gehin, Robert F Storey, Corine Bernaud, et al.
Clinical and Translational Science|August 30, 2020
Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P<sub>1</sub> R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White SubjectsPierre-Eric Juif, Jasper Dingemanse, Peter Winkle, et al.
Clinical Pharmacology in Drug Development|October 16, 2020
Multiple-Dose Pharmacokinetics, Safety, and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Healthy Japanese and Caucasian SubjectsMagda S C Fontes, Jasper Dingemanse, Patricia N Sidharta
Journal of Clinical Pharmacology|September 19, 2015
Lack of Pharmacokinetic Interactions Between Macitentan and a Combined Oral Contraceptive in Healthy Female SubjectsNoémie Hurst, Matthias Pellek, Jasper Dingemanse, et al.
Pageof 25